I think if you look at the first half this year, we're up seven per cent. And if you exclude the pandemic vaccine shipments, we're up one per cent at an underlying level. A little bit slower in Q2 than Q1, simply because of some one-off hits that we took in Q2. So, for example, the suspension of the Rotarix vaccine temporarily in the U.S., now back fully on-stream, but nonetheless had a negative effect and some acceleration in the decline of Avandia, which again, took some of the gloss off the Q2 performance.

Well a very significant amount. Excluding the legal charge that we announced last week, to resolve a lot of our longstanding litigation liabilities in the United States, that EPS number would have been around 29 pence per share, versus the 2.5 pence per share that we announced. So there is obviously a huge difference. And I think, in terms of the underlying performance, excluding legal, that this was, again, a good quarter for the company.

Well unfortunately, I can never tell you we've drawn a line under litigation risk because it is an ever-present threat, particularly if you trade in the United States where litigation unfortunately is a fact of life, in business and in life generally, in the U.S. But what we have been able to do, and we announced it last week, is we've been able to bring to a close or progress toward closure a substantial part of our historic litigation burden, and particularly some of the bigger cases, which have been around for a long time. It was important for us to try and bring closure to these things. And I think we've been able to do it in a way which does bring certainty for our shareholders and does begin to close off or has already closed off a number of these cases. So I'm quite happy with where we've got to and what we were able to announce last week.

Well in any product liability situation, a company has to look at the kind of allegations which have been made and the cost of defence, versus the opportunities to settle. And not unusually, in this situation and in many other situations for us and other companies, we took the view that it was actually in the best interest of the company's shareholders to go ahead and achieve settlement on terms that we believe were reasonable for the company, rather than to go through very long, protracted and potentially very expensive defence in this particular area.

I don't know yet what the FDA action will be. We're waiting to see what they have to say. As you know, of course, they've called this advisory board. They, I'm sure, will take the input and advice that they've received. And we look forward to working with the agency on whatever next steps they deem necessary.

Well what's important in terms of our bolt-on acquisition strategy is we're very focused on the areas where we want to invest, so for example, in the emerging markets, as you described, in areas like Vaccines and in areas like Consumer to underpin our diversification points of the business. So we're very focused, from that point of view. We're also focused on making sure we get good value for money in our acquisitions. So we're not going to pay any price. And that means that the deal flow, if you will, the number of transactions we might execute in any given quarter, will be a little bit up and down. But what's important is we stay disciplined, disciplined in supporting our strategy and disciplined in how we allocate our capital and do it efficiently. I'm actually quite comfortable with the number of transactions we do and I think it's very manageable for us to do this number of transactions. It allows us to stay focused on extracting the value from each deal that we do without becoming overwhelmed with deals and losing sight of the ones that we did last year, for example. So I'm actually pretty comfortable with that flow, as it stands. I'm not going to guarantee that we do this many deals every quarter. Maybe next quarter we'll do more. Maybe we'll do less. It just depends on whether or not we see those opportunities and we can get them done at we believe generates the best return for GSK shareholders.

Well there's no doubt, both in the U.S. and Europe, that price has moved adversely over the last six or nine months. And I'm sure we're going to continue to see that phenomenon over the next year or so, maybe longer, who knows, as governments deal with their deficit reduction. Now in Europe, we've long been used to having year-on-year price reductions, somewhere in the range of about three per cent. At this point in time it's a little hard to tell whether we're going to see something very significant above that rate. My guess is we'll probably see something above that rate, maybe not too much, but we'll see. It's early days.

No, I'm not concerned at all about Consumer, actually. If you look at the underlying performance of our Consumer business, adjusted for the stocking effect last year when we launched Alli weight loss medicine in Europe, which is a very significant pipeline fill for the European business. Remember, we launched every European country on the same day, which is an unprecedented achievement. But of course it meant a lot of stock and inventory went into pipelines all over Europe. If you correct for that, year on year, then our underlying growth for Consumer this year, this quarter, was six per cent.

Well there's no doubt that having five new medicines go into the pipeline is really an unprecedented achievement, I think for the company and I think, maybe, for any company, it's a very significant number. Now that's been achieved through a variety of the changes we've made through R&D to try to create a better sense of accountability and stimulate innovation inside the company and also through our externalisation.

Well let me make a couple of points. First of all, we're absolutely committed to helping our investors and analysts understand our business, which is why we've actually been pretty aggressively increasing the amount of transparency on our business, for example, on our segment reporting and then this quarter around Emerging Markets down to the product level.

The most important signal we're sending around our dividend is confidence in the business and a sustained delivery against the commitment we've made certainly since I've been CEO, of delivering a progressive dividend increase, up again seven per cent this quarter, to 15 pence per share. And I think, if you look over the last several years where you've seen this dividend rise pretty much every quarter, a real evidence of our desire to return cash to shareholders. A substantial portion of our free cash flow goes back to shareholders through the dividend. And this is simply a further demonstration that is our number one priority, to deliver growth in this organisation, be competitive and return the proceeds of that to shareholders in a progressive manner. And that's exactly what we've done again this quarter.

As we go forward, and I've said previously, my sense of confidence for GSK remains undiminished. I think that much of the very major strategic challenges that the group has faced are moving behind us. We've seen a very substantial degree of genericisation headwind now begin to move behind us, particularly by the end of this year. And as we go forward, the contribution of the businesses we've been investing in, like Emerging Markets, Consumer and Vaccines, simply represent bigger and bigger proportions of the total. Our exposure to what I call the 'Western market, white pill', those products which are easy to genericise and copy, is falling all of the time, this quarter only 26 per cent of the overall business. So our exposure on those businesses, which in the past have been so vulnerable, reduces. And of course new pipeline products are arriving all the time for the core R&D business.